Case Report

Coronary spasm and optical coherence tomography defined plaque erosion causing ST-segment-elevation acute myocardial infarction in a patient with COVID-19 pneumonia

Masahiko Nakao (MD)a, Junji Matsuda (MD)a, Mihi Iwai (MD)b, Akira Endo (MD)b, Taishi Yonetsu (MD)a,c, Yasuhiro Otomo (MD)b, Tetsuo Sasano (MD)a

aDepartment of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan
bTrauma and Acute Critical Care Medical Center, Tokyo Medical and Dental University Hospital of Medicine, Tokyo, Japan

cCorresponding author at: Department of Cardiovascular Medicine, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8549, Japan.
E-mail address: t-yonetsu.cvmd@tmd.ac.jp (T. Yonetsu).

Introduction

Infectious diseases caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is called the coronavirus disease 2019 (COVID-19), have become worldwide threats to public health. Although the potential impact of COVID-19 on cardiovascular disease (CVD) has been reported [1,2], the mechanisms or characteristics of acute coronary syndrome occurring in COVID-19 patients has not been elucidated. Of note, there is a paucity of reports on the detailed description of ST-segment elevation myocardial infarction (STEMI) in patients with COVID-19. We describe a case of STEMI which developed during the treatment for severe COVID-19 pneumonia, with detailed information on angiographical and optical coherence tomography (OCT) findings of the culprit lesion.

Case report

An 84-year-old man presented to a local hospital with a 1-day history of fever, chill, and dyspnea. The patient had histories of chronic obstructive pulmonary disease without medication or oxygen therapy and prostate cancer, which had been observed by his primary physician. He quit smoking 10 years before the admission after 54 years of smoking history. He did not have hypertension, dyslipidemia, diabetes, or family history of coronary artery disease.

His initial chest computed tomography demonstrated bibasilar ground-glass opacities (Fig. 1) and his nasopharyngeal swab sample was positive for SARS-CoV-2 on real-time reverse transcriptase polymerase chain reaction assay. He was diagnosed with COVID-19 pneumonia and admitted to the hospital. Despite the medical therapy with oral favipiravir 1600 mg/day, severe hypoxemia was sustained. He was transferred to our hospital for further intensive care. On admission to our hospital, the patient was sedated and intubated, and mechanical ventilation was initiated because of progressive hypoxia. In consideration of hyperinflammatory status in severe COVID-19 pneumonia, immu-
nosuppressive therapy with tocilizumab 600 mg/day was administered for 2 days. In the morning of the 3rd hospital day, the lead I on the continuous electrocardiogram (ECG) monitoring showed ST-segment depression without instability of hemodynamic or respiratory status. The 12-lead ECG revealed ST-segment elevation in the inferior leads (Fig. 2) and cardiologists were consulted.

**Investigations**

The 12-lead ECG demonstrated ST elevation in the inferior leads (Fig. 2). Transthoracic echocardiogram showed a reduced wall motion in infero-posterior region with preserved left ventricular ejection fraction of approximately 50%. Levels of high-sensitive troponin-I and creatine kinase were 20,201 pg/ml (normal <24 pg/ml) and 1288 IU/l (normal <248 IU/l), respectively, at the time of the consultation.

**Management**

Given the sustained ST elevation and regional wall motion abnormality, he was brought to the catheterization laboratory for an emergent coronary angiography after pre-administration of aspirin 200 mg and a bolus injection of intravenous unfractionated heparin 3000 U. His angiograms revealed an intact left coronary artery. In the distal right coronary artery, mild stenosis with a hazy appearance of contrast opacification was identified (Fig. 3). Intracoronary OCT (Dragonfly Optix™, Abbott Vascular, Santa Clara, CA, USA) was performed to evaluate the lesion morphology, which exhibited a folded appearance of the intimal layer indicating spastic arteries [3] and intraluminal thrombi on a plaque with intact fibrous cap indicating OCT-defined plaque erosion [4]. After initial OCT examination, 200 μg of intracoronary isosorbide dinitrate was administered, which resolved diffuse vasospasm in the right coronary artery on angiograms and OCT (Fig. 3) and resulted in the rapid resolution of ST-segment elevation. These examinations confirmed the diagnosis of STEMI caused by coronary vasospasm and OCT-defined plaque erosion. Intravenous nicorandil followed by oral benidipine 4 mg was given for the
prevention of coronary spasm after coronary angiography. In addition, continuous intravenous injection of unfractionated heparin was initiated against coronary thrombosis. Creatine kinase elevated to the peak level of 2336 IU/l at 5 h after catheterization. Left ventricular function was preserved with an ejection fraction of 50%. The treatment for COVID-19 pneumonia was continued without the recurrence of AMI.

Discussion

To the best of our knowledge, this is the first description of a case in which coronary spasm and OCT-defined plaque erosion were confirmed on intracoronary OCT as the causes of STEMI occurring in a patient with COVID-19 pneumonia.

Since the pandemic of COVID-19, the number of patients presenting to hospitals with acute myocardial infarction (AMI) has been reported to have decreased [1], while the patients with COVID-19 were shown to have frequent myocardial injuries or infarctions during the treatment for COVID-19 [2]. Thus, the clinical presentation of AMI may be different in the condition of SARS-CoV-2 infection from those in the normal condition. Nevertheless, the mechanisms and characteristics of AMI in patients with COVID-19 have not been elucidated except an anecdote that more frequent AMI are attributable to non-obstructive coronary arteries than usual [5]. In the present case, coronary spasm and OCT-defined plaque erosion were confirmed as the substrates of coronary thrombosis by the findings of intracoronary OCT.

Coronary spasm is thought to represent a deteriorated endothelial function of coronary arteries [6]. Endothelial injuries in patients with COVID-19 have been reported in pathological investigations [7], suggesting a potential involvement of angiotensin-converting enzyme 2 receptor, which may result in the impairment of the endothelial function of coronary arteries. In addition to the intrinsic endothelial function, it has been reported that chemical mediators may play significant roles in the mechanism of coronary spasm. For example, in patients with anaphylactic syndrome, spastic angina frequently occurs due to the excessive release of inflammatory mediators induced by allergic reaction, which is known as Kounis syndrome. Same as anaphylactic status, patients with COVID-19 are shown to have increased levels of inflammatory cytokines, which deteriorate the systemic conditions leading to acute respiratory distress syndrome or multi-organ failure [8]. As well as the respiratory system, coronary arteries may also be influenced by the inflammatory mediators released in the patients with COVID-19, which potentially induce coronary spasm as shown in the present case. Plaque erosion is the second major mechanism of AMI following plaque rupture [4,9]. Denudation of endothelial layer of coronary arteries complicated with a thrombogenic status of blood results in intracoronary thrombus. Endothelial injuries can be induced by COVID-19 as described above [7], which may expose the subendothelial layer and provide a thrombogenic status on the surface of coronary arteries. Moreover, the COVID-19 reportedly induces systemic coagulopathy, which leads to pulmonary embolization, venous thrombosis, embolic stroke [10], and potentially the susceptibility to coronary thrombosis. In the present case, causal relationship between COVID-19 and coronary thrombosis could not be proven. Nevertheless, considering these potential mechanisms, coronary spasm and plaque erosion might be prevalent pathogeneses of AMI in COVID-19 patients.

Conclusions

Coronary vasospasm and plaque erosion were potential substrates of STEMI in the current COVID-19 patient. Those mechanisms may be accelerated by COVID-19-induced hyperinflammatory and hypercoagulable conditions.

Disclosures

The authors declare that there is no conflict of interest regarding this manuscript.

Sources of funding

None.

Acknowledgments

None.

References

[1] Solomon MD, McNulty EJ, Rana JS, Leong TK, Lee C, Sung S-H, et al. The covid-19 pandemic and the incidence of acute myocardial infarction. N Engl J Med 2020;383:691–3.
[2] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:811–8.
[3] Tanaka A, Shimada K, Torney GJ, Kitabata H, Taguchi H, Fukuda S, et al. Conformational change in coronary artery structure assessed by optical coherence tomography in patients with vasoplastic angina. J Am Coll Cardiol 2011:58:1608–13.
[4] Jia H, Abtahein F, Aguirre AD, Lee S, Chia S, Lowe H, et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol 2013:62:1748–58.
[5] Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, et al. ST-segment elevation in patients with covid-19 – a case series. N Engl J Med 2020;382:2478–80.
[6] Kugiyama K, Yasue H, Okumura K, Ogawa H, Fujimoto K, Nakao K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 1996;94:266–71.
[7] Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395:1417–8.
[8] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4.
[9] Virmanni R, Kolidge FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death. Arterioscler Thromb Vasc Biol 2006;20:1262–75.
[10] Klok FA, Kruip MJHA, Van Der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7.